Regulatory press release1/29/2024, 10:26 AMCompletion of the combination between Novozymes and Chr. Hansen
Regulatory press release1/26/2024, 11:09 AMAll necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
Press release12/20/2023, 2:02 PMUpdate on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
Regulatory press release12/19/2023, 10:54 AMMajor shareholder announcement from Burlington Loan Management DAC
Press release12/12/2023, 4:11 PMUpdate on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
Regulatory press release11/20/2023, 7:03 AMUpdate on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
Regulatory press release10/10/2023, 6:08 AMNovozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
Regulatory press release9/27/2023, 7:23 AMMajor shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP
Regulatory press release9/4/2023, 9:48 AMUpdate on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
Regulatory press release3/30/2023, 4:07 PMNovozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
Regulatory press release3/30/2023, 3:57 PMResolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S
Regulatory press release3/30/2023, 11:11 AMCombination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
Regulatory press release3/28/2023, 10:07 AMUpdate on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
Regulatory press release3/8/2023, 7:00 AMPublication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company